Validation of model of cytochrome P450 2D6: An in silico tool for predicting metabolism and inhibition

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5340-5346

  Kemp, Carol A ^a   Flanagan, Jack U ^b   Van Eldik, Annamaria J ^a   Maréchal, Jean Didier ^a   Wolf, C Roland ^b   Roberts, Gordon C K ^a   Paine, Mark J I ^b   Sutcliffe, Michael J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALICINE; CINCHONIDINE; CINCHONINE; CYTOCHROME P450 2D6; HEME; NITROGEN; QUINIDINE; RUBOXISTAURIN; SULFONAMIDE; YOHIMBINE;

ACCURACY; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DATA BASE; ENZYME ACTIVE SITE; INHIBITION KINETICS; METABOLISM; MODEL; PREDICTION; VALIDATION PROCESS;

BINDING SITES; CYTOCHROME P-450 CYP2D6; DATABASES, FACTUAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6044232040     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049934e     Document Type: Article

References (34)

1. Jones, B. C.; Tyman, C. A.; Smith, D. A. Identification of the cytochrome P450 isoforms involved in the O-demethylation of 4-nitroanisole in human liver microsomes. Xenobiotica 1997, 27, 1025-1037.
2. Slaughter, R. L.; Edwards, D. J. Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. 1995, 29, 619-624.
3. Spina, E.; Avenoso, A.; Scordo, M. G.; Ancione, M.; Madia, A.; et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol. 2002, 22, 419-423.
4. Kumar, G. N.; Rodrigues, A. D.; Buko, A. M.; Denissen, J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1998, 277, 423-431.
5. Michalets, E. L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998, 18, 84-112.
6. Langdon, W. B.; Barrett, S. J.; Buxton, B. F. Predicting biochemical interactions-human P450 2D6 enzyme inhibition. In Congress on Evolutionary Computation; IEEE Press: Canberra, Australia, 2003.
7. Susnow, R. G.; Dixon, S. L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
8. Ekins, S.; Berbaum, J.; Harrison, R. K. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab. Dispos. 2003, 31, 1077-1080.
9. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999, 9, 477-489.
10. Strobl, G. R.; von Kruedener, S.; Stockigt, J.; Guengerich, F. P.; Wolff, T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J. Med. Chem. 1993, 36, 1136-1145.
11. Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 2002, 6, 439-446.
12. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 2002, 45, 2213-2221.
13. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
14. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided. Mol. Des. 1997, 11, 425-445.
15. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
16. Kirton, S. B.; Kemp, C. A.; Tomkinson, N. P.; St-Gallay, S.; Sutcliffe, M. J. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 2002, 49, 216-231.
17. Guengerich, F. P.; Miller, G. P.; Hanna, I. H.; Martin, M. V.; Leger, S.; et al. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 2002, 41, 11025-11034.
18. 2, then the model can be deemed to be predictive.
19. Developmental Therapeutics Program, National Cancer Institute; http://dtp.nci.nih.gov/docs/idrugs/chemdata.html. For database searching, use the URL http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp.
20. Paine, M. J.; McLaughlin, L. A.; Flanagan, J. U.; Kemp, C. A.; Sutcliffe, M. J.; et al. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J. Biol. Chem. 2003, 278, 4021-4027.
21. Flanagan, J. U.; Marechal, J. D.; Ward, R.; Kemp, C. A.; McLaughlin, L. A.; et al. Phe120 contributes to the regiospecificity of CYP2D6: Mutation leads to the formation of a novel dextromethorphan metabolite. Biochem. J. 2004, 380, 353-360.
22. Smith, G.; Modi, S.; Pillai, I.; Lian, L. Y.; Sutcliffe, M. J.; et al. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity. Biochem. J. 1998, 331, 783-792.
23. Silicon Graphics Inc., Mountain View, CA.
24. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779-815.
25. Poulos, T. L.; Finzel, B. C.; Howard, A. J. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 1986, 25, 5314-5322.
26. Hasemann, C. A.; Ravichandran, K. G.; Peterson, J. A.; Deisenhofer, J. Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. J. Mol. Biol. 1994, 236, 1169-1185.
27. Cupp-Vickery, J.; Anderson, R.; Hatziris, Z. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3050-3055.
28. Ravichandran, K. G.; Boddupalli, S. S.; Hasemann, C. A.; Peterson, J. A.; Deisenhofer, J. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 1993, 261, 731-736.
29. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. J. Inorg. Biochem. 2000, 81, 183-190.
30. SYBYL; version 6.81, 2002; Tripos Associates: St. Louis, MO.
31. InsightII, 2003; Accelrys Inc.: San Diego, CA.
32. http://www.gentest.com/products/HTS_kits/HTS_Links.shtm.
33. Prism, version 3.0, 2002; GraphPad; San Diego, CA.
34. GraFit, version 5.0.4, 2002; Erithacus Software Ltd.: Surrey, U.K.